Comparison of On-Label Treatment Persistence in Real-World Patients With Psoriatic Arthritis Receiving Guselkumab versus Subcutaneous Interleukin-17A Inhibitors

The above graphical abstract represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online (see “read the peer-reviewed publication” opposite).